Merck stock holds support as 2025 revenue and profit stay in view

Merck & Co. (US58933Y1055) stock is shaped by a 2025 base of $64.2 billion in revenue and $7.65 in adjusted earnings per share, while first-quarter 2026 sales reached $15.5 billion. Those figures frame the share story even without a fresh company release in the search set, because they show the scale of the business against a current quarterly run rate.

2025 base still matters

For 2025, Merck reported $64.2 billion in worldwide sales, $7.65 in adjusted EPS, and $15.5 billion in first-quarter 2026 revenue. The comparison is clear: Q1 2026 sales equal about 24.1% of the 2025 full-year total, which gives investors a concrete read on how the year started relative to the prior annual base.

That ratio matters because Merck is still a large, earnings-led pharmaceutical group, and the market tends to anchor around revenue durability, patent-cycle pressure, and the pace of new product offsets. In that context, the 2025 figures provide the most recent full-year reference point, while Q1 2026 gives the latest operational checkpoint.

Quarterly scale at $15.5 billion

The Q1 2026 sales figure of $15.5 billion is the freshest period metric in the body and it sits against the much larger 2025 annual figure. The second comparison is earnings-based: $7.65 in adjusted EPS for 2025 versus the quarterly revenue run rate in early 2026 shows that the company remains profitable at a scale that supports dividend and pipeline investment decisions.

For investors, the key point is not a single-day move but the balance between current-quarter execution and the prior-year base. A business that generated $64.2 billion in 2025 and $15.5 billion in one quarter of 2026 remains sensitive to growth in oncology, vaccines, and animal health, because those segments can influence the next earnings inflection.

Key products drive mix

Key products such as Keytruda continue to define the company mix, and that makes segment-level momentum more important than a generic company description. The product family remains central to how Merck translates sales into earnings, especially when the annual comparison is against a $64.2 billion revenue base.

Merck’s broader product portfolio also matters because it determines whether quarterly sales growth can stay aligned with the 2025 reference point. A few billion dollars in quarterly revenue from one or two core therapies can change the earnings profile more quickly than a broad corporate narrative would suggest.

Stock level context

The stock-level context in this article is the company’s current fundamental scale, not a live quote, and the most usable market anchor in the evidence set is the 2025 revenue base of $64.2 billion. That figure is the clearest dated market-relevance reference available here, paired with the 2025 adjusted EPS of $7.65 and the Q1 2026 sales figure of $15.5 billion.

Merck & Co. remains a large-cap health care name with a revenue profile that can absorb quarter-to-quarter swings. The latest visible numbers point to a company still operating from a high annual base, with the next read-through likely to come from how current-quarter sales compare with the 2025 full-year benchmark.